Operationalizing Access at Scale As manufacturers increasingly manage GLP-1s as long-term portfolios, platforms like GoodRx are becoming essential for connecting patients to innovation
Announced on September 17, 2025, by parent company Eli Lilly and Company, the phase 3 ACHIEVE-3 trial compared orforglipron to oral semaglutide across 4 active treatment arms, assessing glycemic control and weight loss
Inconsistent blood levels mean inconsistent appetite suppression, inconsistent blood sugar control, and potentially slower weight loss progress
Ozempic is a brand-name formulation of semaglutide that has earned FDA approval to treat patients with Type 2 Diabetes
The quest to find a great glutathione soap can be overwhelming because there are so many options
For researchers investigating the intricate dance of hormones in appetite control, Cagrilintide offers a focused lens